Navigation Links
Genesis Biopharma Conference Call and Webcast Reminder
Date:6/28/2011

LOS ANGELES, June 28, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, is holding a conference call with the investment community tomorrow, Wednesday, June 29, 2011 at Noon Eastern (9:00 a.m. Pacific).  The Company's Chairman and Chief Executive Officer, Anthony J. Cataldo, will provide an update on the business, and discuss the clinical and commercial development plans for the Company's new autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.  There will also be a question and answer session following the presentation.

Individuals interested in listening to the conference call may do so by dialing 888-634-9408 for domestic callers, or 706-679-0879 for international callers, or from the webcast on the investor relations section of the Company's Web site at www.genesis-biopharma.com.  A slide presentation will accompany the call and webcast, and will be available on the Company website.

A telephone replay will be available through July 1, 2011 by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering the Conference ID #: 78126182.  The webcast will be available on the Company's Web site for 60 days following the completion of the call.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general.  Forward-looking statements speak only as of the date they are made.  The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
2. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
3. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
4. ThermoGenesis Announces China Customer Implements Cord Blood Products
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
7. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
8. Announcing ValGenesis On-Demand SaaS Solution
9. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
10. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
11. Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)...   Biocept, Inc . (NASDAQ: ... actionable liquid biopsy tests to improve the management ... its Target Selectorâ„¢ Circulating Tumor Cell platform demonstrated ... of actionable biomarkers in patients with metastatic breast ... Cannon Research Institute (SCRI), the research arm of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
(Date:12/7/2016)... The report "Acrylic Processing Aid Market by Polymer Type (PVC), Fabrication ... - Global Forecast to 2026", published by MarketsandMarkets, the global market size was ... by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
Breaking Biology News(10 mins):